A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study PC Austin, P Grootendorst, GM Anderson Statistics in medicine 26 (4), 734-753, 2007 | 1328 | 2007 |
The cost of drug development: a systematic review S Morgan, P Grootendorst, J Lexchin, C Cunningham, D Greyson Health policy 100 (1), 4-17, 2011 | 695 | 2011 |
Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. AR Levy, BJ O'Brien, C Sellors, P Grootendorst, D Willison The Canadian journal of clinical pharmacology= Journal canadien de …, 2003 | 554 | 2003 |
Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study PC Austin, P Grootendorst, SLT Normand, GM Anderson Statistics in medicine 26 (4), 754-768, 2007 | 263 | 2007 |
Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey P Grootendorst, D Feeny, W Furlong Medical care 38 (3), 290-299, 2000 | 256 | 2000 |
Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence J Lexchin, P Grootendorst International Journal of Health Services 34 (1), 101-122, 2004 | 245 | 2004 |
An empirical analysis of milk addiction MC Auld, P Grootendorst Journal of health economics 23 (6), 1117-1133, 2004 | 190 | 2004 |
A comparison of alternative models of prescription drug utilization PV Grootendorst Health Economics 4 (3), 183-198, 1995 | 159 | 1995 |
Cost analysis of dialysis treatments for end-stage renal disease (ESRD). R Goeree, J Manalich, P Grootendorst, ML Beecroft, DN Churchill Clinical and Investigative medicine. Medecine Clinique et Experimentale 18 …, 1995 | 153 | 1995 |
Dental insurance, income and the use of dental care in Canada T Bhatti, Z Rana, P Grootendorst J Can Dent Assoc 73 (1), 57, 2007 | 140 | 2007 |
Does it matter whom and how you ask? Inter-and intra-rater agreement in the Ontario Health Survey PV Grootendorst, DH Feeny, W Furlong Journal of clinical epidemiology 50 (2), 127-135, 1997 | 135 | 1997 |
Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada P Contoyannis, J Hurley, P Grootendorst, SH Jeon, R Tamblyn Health economics 14 (9), 909-923, 2005 | 118 | 2005 |
Estimating the clinical cost of drug development for orphan versus non-orphan drugs K Jayasundara, A Hollis, M Krahn, M Mamdani, JS Hoch, P Grootendorst Orphanet journal of rare diseases 14, 1-10, 2019 | 112 | 2019 |
Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey GEJ Faulkner, P Grootendorst, VH Nguyen, T Andreyeva, ... International Journal of Behavioral Nutrition and Physical Activity 8, 1-14, 2011 | 106 | 2011 |
Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research KM Johnston, P Gustafson, AR Levy, P Grootendorst Statistics in medicine 27 (9), 1539-1556, 2008 | 99 | 2008 |
Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. P Grootendorst The Canadian journal of clinical pharmacology= Journal canadien de …, 2002 | 90 | 2002 |
Becoming the best mom that I can: women's experiences of managing depression during pregnancy–a qualitative study HA Bennett, HS Boon, SE Romans, P Grootendorst BMC women's health 7, 1-14, 2007 | 85 | 2007 |
Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs PV Grootendorst, LR Dolovich, BJ O'Brien, AM Holbrook, AR Levy Cmaj 165 (8), 1011-1019, 2001 | 83 | 2001 |
Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia JK Marshall, PV Grootendorst, BJ O'Brien, LR Dolovich, AM Holbrook, ... Cmaj 166 (13), 1655-1662, 2002 | 80 | 2002 |
Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology Y Li, MR Abbaspour, PV Grootendorst, AM Rauth, XY Wu European Journal of Pharmaceutics and Biopharmaceutics 94, 170-179, 2015 | 79 | 2015 |